Capital markets check-in; plus Belgium’s prodigal son returns
What’s next for Galapagos with Stoffels at the helm. U.S. Senate’s Califf capers. Gottlieb stirs the pot. Emerging Company Spotlight
By Jeff Cranmer, Executive Editor
February 1, 2022 2:46 AM UTC
BioCentury
On the latest BioCentury This Week podcast, BioCentury’s senior editors discuss the state of the capital markets for biotech as well as Paul Stoffels’ homecoming in his new role as CEO of Belgian bellwether Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG).
Washington Editor Steve Usdin delivers the latest scuttlebutt on Rob Califf’s nomination as the next FDA commissioner and recaps his conversation with former FDA head Scott Gottlieb on the debut episode of The BioCentury Show, a new open-access series featuring in-depth conversations with leaders across the global life sciences ecosystem.
In this week’s Emerging Company Spotlight segment, Editor in Chief Simone Fishburn and Associate Editor Stephen Hansen discuss Third Rock’s Septerna Inc., which launched to bring new life to GPCRs with Bob Lefkowitz’s latest technology; Mark Chao-led TenSixteen Bio Inc., which last week raised a $40 million series A round to interrogate a new source of disease-causing mutations in hematopoietic stem cells; and Cellino Biotech Inc., which last week raised $80 million in its series A to bring iPSC-derived cell therapies to the masses through an automated manufacturing process that can commercially scale the reprogramming of stem cells into therapeutic cells.
Sponsorship and underwriting packages are available for BioCentury’s webinars, podcasts and surveys. For more information, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.
